Investigational drug · Phase 3
FDC laroprovstat
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypercholesterolemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "FDC laroprovstat"
First trial start
2026
Dec 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FDC laroprovstat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypercholesterolemia
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "FDC laroprovstat" as an intervention, largest first.
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07619131 · 600 participants (planned) · Start Aug 12, 2026 · Primary completion Jul 30, 2027
Drug: Laroprovstat; Rosuvastatin 1 and 6 more · For: Hypercholesterolaemia
Sites: Dothan, Alabama; Chandler, Arizona; Phoenix, Arizona · 152 sites in all
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve PatientsPivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07930507 · 204 participants (planned) · Start Dec 21, 2026 · Primary completion Oct 11, 2027
Drug: Laroprovstat; Rosuvastatin 1 and 5 more · For: Hypercholesterolemia
Sites: Beijing, China; Chifeng, China; Guangzhou, China · 42 sites in all
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With HypercholesterolaemiaPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07619118 · 200 participants (planned) · Start Sep 10, 2026 · Primary completion May 28, 2027
Drug: Placebo to match laroprovstat/rosuvastatin 1,2,3; Placebo to match laroprovstat/rosuvastatin 4 and 5 more · For: Hypercholesterolaemia
Sites: Sun City West, Arizona; Gardena, California; Lomita, California · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypercholesterolemia
- SHR-1918Phase 37 trials
Beijing Suncadia Pharmaceuticals Co., Ltd · Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia
- AG2304RPhase 31 trial
Ahn-Gook Pharmaceuticals Co.,Ltd · Hypercholesterolemia
- AG2304TPhase 31 trial
Ahn-Gook Pharmaceuticals Co.,Ltd · Hypercholesterolemia
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.